Bank of New York Mellon Corp Boosts Stake in Ocugen, Inc. (NASDAQ:OCGN)

Bank of New York Mellon Corp increased its position in Ocugen, Inc. (NASDAQ:OCGN - Free Report) by 2,760.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 751,819 shares of the company's stock after purchasing an additional 725,536 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.29% of Ocugen worth $1,165,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in OCGN. State Board of Administration of Florida Retirement System bought a new position in shares of Ocugen during the first quarter valued at approximately $132,000. Tidal Investments LLC bought a new stake in Ocugen during the 1st quarter valued at about $108,000. Baader Bank Aktiengesellschaft bought a new stake in shares of Ocugen during the second quarter valued at approximately $35,000. Headlands Technologies LLC purchased a new position in Ocugen in the 1st quarter worth approximately $66,000. Finally, David J Yvars Group purchased a new position in Ocugen in the 1st quarter worth approximately $35,000. 10.27% of the stock is owned by hedge funds and other institutional investors.

Ocugen Stock Down 2.6 %

OCGN traded down $0.03 during trading on Friday, hitting $1.11. 6,182,764 shares of the company's stock traded hands, compared to its average volume of 6,663,607. Ocugen, Inc. has a 12-month low of $0.35 and a 12-month high of $2.11. The company's 50 day simple moving average is $1.35 and its two-hundred day simple moving average is $1.46. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $285.66 million, a price-to-earnings ratio of -4.44 and a beta of 3.69.

Ocugen (NASDAQ:OCGN - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.02. The firm had revenue of $1.14 million during the quarter. During the same period in the prior year, the firm earned ($0.10) earnings per share. Analysts predict that Ocugen, Inc. will post -0.2 earnings per share for the current fiscal year.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.